X

Trial Profile

Clinical study of 177Lu-rhPSMA-10.1 and 177Lu-PSMA I&T

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lutetium 177 rhPSMA (Primary) ; Lutetium-177 zadavotide guraxetan (Primary)
Indications Prostate cancer
Focus Therapeutic Use

Most Recent Events

05 Jul 2023 New trial record
28 Jun 2023 According to a Blue Earth Therapeutics media release, results from this study by BET collaborators at University Hospital Augsburg, Augsburg, Germany, were presented by Ralph Bundschuh.
28 Jun 2023 According to a Blue Earth Therapeutics media release, results from this trial were presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com